Peptide Research Week in Review: 16-21 September 2026
TL;DR: This week: CBS's LegitScript ad exposé, compounders vs Lilly's biologic bid, and the 24 Sep Seventh Circuit hearing preview.
What Happened in Peptide Research This Week (16-21 Sep 2026)?
One underlying story ran through the whole week, told from three different angles, and all three point at the same 24 September court date. CBS News opened the week on 16 September with an investigation into how more than 80 businesses selling unapproved retatrutide used LegitScript certification badges to get prescription-drug ads approved on major platforms.[1] A 10 September Reason analysis, which our own coverage picked up on 20 September, reported that the compounding-pharmacy trade group the Outsourcing Facilities Association is publicly opposing Eli Lilly's push to have retatrutide reclassified as a biologic, warning it would close the compounding exemption the industry currently relies on.[2] And with oral arguments in Eli Lilly and Company v. Kennedy now five days out, we previewed on 19 September what each side is expected to argue when the Seventh Circuit hears the case on 24 September.[3]
None of these three stories is a new clinical readout — retatrutide's most recent trial news remains the 23 July TRIUMPH-2/TRIUMPH-3 topline results and the 15 September announcement that full TRIUMPH-2 data will be presented at EASD 2026 on 30 September.[6] Instead, this week was about the regulatory and legal machinery around retatrutide: who is allowed to advertise it, who is allowed to compound it, and which federal court will decide how it gets classified in the first place.
What Did CBS News' LegitScript Investigation Find?
What was found: More than 80 businesses selling or advertising retatrutide displayed LegitScript certification badges — one of the only routes healthcare advertisers have to get prescription-drug ads approved on Meta, Google, YouTube and LinkedIn. At least 35 of those businesses showed the badge on the exact page promoting retatrutide.[1]
Why it matters: A compliance certification tells a platform a business meets defined marketing and licensing criteria; it says nothing about what is actually in a vial a customer receives. CBS's reporting describes the badge lending an appearance of legitimacy to advertising for a drug that has not been approved by any regulator anywhere.[1]
Full breakdown: How Did 80+ Illegal Retatrutide Sellers Get a "Trusted" Certification Seal?
The story sits inside Eli Lilly's wider black-market enforcement push: Lilly has said it has referred more than 200 entities selling illegal retatrutide to the FDA, the Department of Justice, state attorneys general and law enforcement, and sued six sellers directly on 12 August 2026.[4] The LegitScript findings add a specific mechanism to that pattern — how some sellers reached mainstream ad audiences at all.
Why Are Compounding Pharmacies Fighting Lilly's Biologic Bid?
The dispute: Eli Lilly wants the FDA to classify retatrutide as a biologic; the FDA has instead remanded the classification question rather than ruling outright, prompting Lilly's lawsuit. A biologic designation carries its own exclusivity protections, but it would also close the 503A/503B compounding exemption pathway that currently allows pharmacies to compound retatrutide as a conventional drug.[2]
Who's arguing what: The Outsourcing Facilities Association, representing compounding pharmacies, is siding with the FDA's more cautious position, framing Lilly's push as commercially motivated rather than scientifically necessary.[2]
Full breakdown: Why Compounding Pharmacies Are Fighting Lilly's Retatrutide Biologic Bid
What's at Stake at the 24 September Seventh Circuit Hearing?
The classification fight reaches its next milestone on 24 September, when the Seventh Circuit hears oral arguments in Eli Lilly and Company v. Kennedy. Lilly will press the court to order the FDA to classify retatrutide as a biologic outright; the FDA will defend its decision to remand the question instead of ruling on it directly.[3] The case has been running since Lilly first sued the FDA over the classification question in September 2024, and the court set the 24 September argument date back in August.[5]
The outcome decides more than a label. Biologic status affects exclusivity protections for Lilly, the compounding exemption compounding pharmacies currently rely on, and how retatrutide is eventually marketed once the FDA reviews Lilly's Q1 2027 Biologics License Application — which is why both the compounding industry and Lilly's black-market enforcement effort are watching the same courtroom.
Full breakdown: What to Expect at the Retatrutide Seventh Circuit Hearing · background: how the court set the 24 Sep date
How Do This Week's Three Stories Connect?
Read separately, LegitScript's advertising badges, compounding-pharmacy trade politics and a federal appellate hearing look like unrelated stories. Read together, they are the same regulatory fight viewed from three seats in the room: consumer-facing advertising (LegitScript), the industry that would lose its compounding exemption if Lilly wins (the OFA), and the court that will settle the underlying classification question (the Seventh Circuit). Whichever way the court rules, the advertising and compounding questions this week's stories raise will not disappear — they will just be argued under whichever regulatory pathway the judges choose.
What Happens Next?
| Track | Next milestone | Expected timing |
|---|---|---|
| Eli Lilly v. Kennedy | Seventh Circuit oral arguments | 24 September 2026 |
| Retatrutide (Lilly) | Full TRIUMPH-2 data presented | EASD 2026, Milan, 30 September 2026 |
| Retatrutide BLA (Lilly) | FDA filing submission | Q1 2027 |
| Compounding pathway (OFA vs Lilly) | Depends on Seventh Circuit ruling | No date announced |
| Velox Peptides | Next weekly research roundup | 28 September 2026 |
What Should UK and Irish Researchers Take From This Week?
All three stories concern US advertising law, US compounding-pharmacy regulation and a US federal appellate court — none of it changes the Human Medicines Regulations 2012 or MHRA guidance governing lawful research-reagent supply in Great Britain and Northern Ireland. The recurring lesson generalises anyway: a certification badge, a trade-group press release or a court filing all describe the regulatory status of a consumer-facing pharmaceutical product, not the identity or purity of a specific batch of research reagent. See our guide on whether research peptides are legal in the UK for the fuller regulatory picture.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA, HPRA or FDA. Not for human or veterinary consumption. See our Research Use Policy and MHRA Statement.
References
- CBS News. A trusted seal made these websites look legit. The weight-loss drug they sold wasn't. 16 September 2026. cbsnews.com. Full breakdown: veloxpeps.com
- Reason. Can a new weight loss treatment escape the legal and regulatory thicket? 10 September 2026. reason.com. Full breakdown: veloxpeps.com
- Velox Peptides. What to Expect at the Retatrutide Seventh Circuit Hearing (24 September 2026). veloxpeps.com
- Eli Lilly and Company (PR Newswire). Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. 12 August 2026. prnewswire.com
- Velox Peptides. Retatrutide FDA Case: Seventh Circuit Sets 24 September Hearing Date. veloxpeps.com
- Eli Lilly and Company. Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026. Press release, 15 September 2026. investor.lilly.com
- Velox Peptides. Peptide Research Week in Review: 9-15 September 2026, for the preceding week's coverage. veloxpeps.com
Frequently Asked Questions
What's the biggest peptide research story this week (16-21 September 2026)?
One underlying fight dominated from three angles. CBS News (16 September) reported that 80+ businesses used LegitScript certification badges to advertise unapproved retatrutide. Compounding-pharmacy trade group the Outsourcing Facilities Association went public opposing Eli Lilly's push to have retatrutide classified as a biologic. And oral arguments in Eli Lilly v. Kennedy, the case that will decide that classification question, are scheduled for 24 September at the Seventh Circuit.
What did CBS News' LegitScript investigation find?
CBS News reported on 16 September 2026 that more than 80 businesses advertising or selling unapproved retatrutide displayed LegitScript certification badges, one of the main routes to running prescription-drug ads on Meta, Google, YouTube and LinkedIn. At least 35 of those businesses displayed the badge on the same page as their retatrutide ads.
Why are compounding pharmacies opposing Lilly's biologic classification push?
A 10 September 2026 Reason analysis reported that the Outsourcing Facilities Association, a US compounding-pharmacy trade group, is backing the FDA's position and calling Lilly's biologic push a money grab, because a biologic designation would close the 503A/503B compounding exemption pathway that currently lets pharmacies compound retatrutide.
What happens at the 24 September Seventh Circuit hearing?
Judges will hear oral arguments in Eli Lilly and Company v. Kennedy, where Lilly is pressing the court to order the FDA to classify retatrutide as a biologic outright, while the FDA defends its decision to remand the classification question rather than rule immediately. The outcome will determine which regulatory pathway, and which exclusivity and compounding rules, ultimately apply to retatrutide.
Does any of this week's news affect UK research-reagent supply?
No. All three stories concern US advertising practices, US compounding-pharmacy law and US federal court litigation over an unapproved investigational drug's regulatory classification. None of it changes the Human Medicines Regulations 2012 or MHRA guidance governing lawful research-reagent supply in the UK. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, not a medicine, for qualified UK researchers.